share_log

新銳醫藥：2023年報

NEW RAY MEDIC: 2023 Annual Report

Hong Kong Stock Exchange ·  Apr 24 08:27
Summary by Moomoo AI
新銳醫藥國際控股有限公司（新銳醫藥）於二零二三年錄得收益約50.2百萬港元，較上一年度的約89.8百萬港元減少約44.1%。毛利約為12.9百萬港元，較上年的約13.2百萬港元略減約2.3%。公司擁有人應佔淨虧損約為22.2百萬港元，較上年的虧損約77.9百萬港元減少約71.5%。董事會不建議派付截至二零二三年十二月三十一日止年度之末期股息。於二零二三年十二月三十一日，本集團之資產負債比率為零。本集團主要業務為於中國從事醫藥產品分銷及貿易及提供營銷及推廣服務。
新銳醫藥國際控股有限公司（新銳醫藥）於二零二三年錄得收益約50.2百萬港元，較上一年度的約89.8百萬港元減少約44.1%。毛利約為12.9百萬港元，較上年的約13.2百萬港元略減約2.3%。公司擁有人應佔淨虧損約為22.2百萬港元，較上年的虧損約77.9百萬港元減少約71.5%。董事會不建議派付截至二零二三年十二月三十一日止年度之末期股息。於二零二三年十二月三十一日，本集團之資產負債比率為零。本集團主要業務為於中國從事醫藥產品分銷及貿易及提供營銷及推廣服務。
Novi Pharmaceuticals International Holdings Limited (Novi Pharmaceuticals) recorded revenues of approximately HK$50.2 million in 2013, down approximately 44.1% from approximately HK$89.8 million in the previous year. Gross profit was approximately HK$12.9 million, down approximately 2.3% from approximately HK$13.2 million a year earlier. Company owners accounted for a net loss of approximately HK$22.2 million, a decrease of approximately 71.5% from the previous year's loss of approximately HK$77.9 million. The Board of Directors does not propose the payment of a final dividend for the year ended 31 December 2013. On 31 December 2013, the Group's asset and debt ratio was zero. The Group's main business is the distribution and trade of pharmaceutical products in China and the provision of marketing and promotion services.
Novi Pharmaceuticals International Holdings Limited (Novi Pharmaceuticals) recorded revenues of approximately HK$50.2 million in 2013, down approximately 44.1% from approximately HK$89.8 million in the previous year. Gross profit was approximately HK$12.9 million, down approximately 2.3% from approximately HK$13.2 million a year earlier. Company owners accounted for a net loss of approximately HK$22.2 million, a decrease of approximately 71.5% from the previous year's loss of approximately HK$77.9 million. The Board of Directors does not propose the payment of a final dividend for the year ended 31 December 2013. On 31 December 2013, the Group's asset and debt ratio was zero. The Group's main business is the distribution and trade of pharmaceutical products in China and the provision of marketing and promotion services.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more